Anticancer Drugs Oncology Pharmacology Physiotherapy Ramucirumab

Ramucirumab (26)

In this article, we will discuss Ramucirumab (26). So, let’s get started.

Use in Specific Population 
Pregn*ncy Category C
Risk Summary
Based on its mechanism of action, Ramucirumab may cause fetal harm. Animal models link angiogenesis, VEGF and
VEGF Receptor 2 (VEGFR2) to critical aspects of female reproduction, embryo-fetal development, and post-natal
development. There are no adequate or well controlled studies of ramucirumab in pregn*nt women. If this drug is used
during pregnancy, or if the patient becomes pregn*nt while taking this drug, apprise the patient of the potential hazard to a

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.